-
Product Insights
P2X Purinoceptor 3 – Drugs In Development, 2023
Global Markets Direct’s P2X Purinoceptor 3 provides in depth analysis on P2X Purinoceptor 3 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P2X Purinoceptor 3 targeted therapeutics...
-
Product Insights
P2X Purinoceptor 7 – Drugs In Development, 2023
Global Markets Direct’s P2X Purinoceptor 7 provides in depth analysis on P2X Purinoceptor 7 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P2X Purinoceptor 7 targeted therapeutics...
-
Product Insights
Purinergic Receptor P2X – Drugs In Development, 2023
Global Markets Direct’s Purinergic Receptor P2X provides in depth analysis on Purinergic Receptor P2X targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Purinergic Receptor P2X targeted therapeutics...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JNJ-8942 in Depression
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JNJ-8942 in Depression report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.JNJ-8942 in Depression Drug Details:JNJ-8942 is under development for the treatment of depression and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JNJ-8942 in Bipolar Disorder (Manic Depression)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JNJ-8942 in Bipolar Disorder (Manic Depression) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.JNJ-8942 in Bipolar Disorder (Manic Depression) Drug Details:JNJ-8942 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AK-1780 in Pain
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AK-1780 in Pain Drug Details:AKP-23494954 (RQ-00466479) is under development for the treatment of pain including neuropathic...
-
Product Insights
Net Present Value Model: BLU-5937
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model BLU-5937 Drug Details BLU-5937 (NEO-5937) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PAX-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry PAX-101 Drug Details Suramin (PAX-101) is under development for the treatment of human African...